California-based Vascular Dynamics Inc. (VDI) is sponsoring a new clinical trial, called CALM-2 (Controlling And Lowering blood pressure with MobiusHD), of a novel endovascular approach to treat patients with drug-resistant hypertension. St. Bartholomew’s Hospital in London is helping to lead efforts in the U.K. as a key study site.

A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and potentially prevent cancer metastasis, according to a study published in Science Translational Medicine.

Foldax Inc. announced the U.S. Food and Drug Administration (FDA) has granted investigative device exemption (IDE) approval for an Early Feasibility Study of the Tria surgical aortic heart valve to treat aortic valve disease.

Epsilon Imaging recently launched the new EchoInsight Pro Starter configuration for those programs that may be budget constrained or just getting started with the incorporation of strain imaging into echo studies. The EchoInsight Pro Starter configuration starts with a two-seat bundle at an affordable, discounted package price, and can scale to up to six client seats.

Corindus Vascular Robotics Inc. is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use the CorPath GRX System in neurovascular intervention. CorPath GRX, the second-generation robotic platform, received FDA clearance for percutaneous coronary intervention (PCI) in 2016 and peripheral vascular intervention (PVI) in 2018. Upon successful FDA clearance, CorPath GRX would become the world’s first and only robotic platform indicated for use in PCI, PVI and neurovascular intervention (NVI).

Circle Cardiovascular Imaging and Galgo Medical recently announced an agreement for distribution and joint development with respect to magnetic resonance imaging (MRI) scanner application products and workflows, with corresponding post-processing capabilities. The focus will be to improve cardiac MRI workflows and diagnostic tools to expand accessibility and use of the modality to electrophysiology procedures such as atrial fibrillation and ventricular tachycardia ablations.

The U.S. Department of Health and Human Services (HHS) has proposed a new rule to support seamless and secure access, exchange and use of electronic health information (EHI).

Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo Occluder, the world's first commercially-approved medical device for transcatheter patent ductus arteriosus (PDA) closure in babies weighing as little as two pounds. The self-expanding, wire mesh device developed by Abbott is inserted through a small incision in the leg and guided through vessels to the heart, where it is placed to seal the opening of the heart.